Palisade Bio Inc
PALI
NASDAQ
Biotechnology
$2.14
USD
-0.01 (-0.47%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $368.58M
Volume 1.6M
Revenue
$500,000
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-31.94M
TTM
-169.7%
YoY
Operating Cash Flow
$-18.19M
TTM
-88.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 |
Selling, General & Administrative | 1.2 | 1.5 | 3.8 | 4.4 | 4.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.8 | 2.9 | 10.0 | 10.7 | 12.2 |
Operating Income | -2.8 | -2.9 | -10.0 | -10.7 | -11.7 |
EBITDA | -2.8 | -2.9 | -10.0 | -10.7 | -11.7 |
Other Income / Expense | 0.1 | 0.1 | 1.1 | 1.1 | 1.1 |
Total Other Income / Expense | 0.1 | 0.1 | 1.1 | 1.1 | 1.1 |
Income Before Income Taxes | -2.8 | -2.9 | -8.9 | -9.6 | -10.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.8 | -2.9 | -8.9 | -9.6 | -10.6 |
Consolidated Net Income / Loss | -2.8 | -2.9 | -8.9 | -9.6 | -10.6 |
Net Income Attributable to Common Shareholders | -2.8 | -2.9 | -8.9 | -9.6 | -10.6 |
Basic EPS | -$0.58 | -$0.38 | -$0.04 | -$0.05 | -$0.05 |
Diluted EPS | -$0.58 | -$0.38 | -$0.04 | -$0.05 | -$0.05 |
Basic Shares Outstanding | 4.8M | 7.5M | 205.6M | 209.7M | 211.4M |
Diluted Shares Outstanding | 4.8M | 7.5M | 205.6M | 209.7M | 211.4M |